Author Index Vol. 51, Suppl. 1, 2008
Satoshi Kitai(Kindai University), Yo Sasaki, Kootaro Shimada, Kathryn Effendi(Keio University), Chie Tatsumi(Kindai University), Satoru Hagiwara(Kindai University Hospital), Hironori Haga(Kyoto University), Hiroko Oka, Masatoshi Kudo(Kindai University), Yasunori Minami(Kindai University), Shunsuke Takahashi(Kanagawa Dental University), Joon Koo Han(Seoul National University), Yoji Maetani, Toshihito Seki(Kansai Medical University), Hobyung Chung(Kindai University), Yukio Osaki, Seung Kew Yoon(The Catholic University of Korea Seoul St. Mary's Hospital), Yohei Masugi(Tokai University), Emi Ishikawa, Kaori Togashi(Kyoto University), Yutaka Asakuma, Hyo Won Eun, Shigeki Arizono(Kobe City Medical Center General Hospital), Taisuke Ueda, Rie Irie, Kazuomi Ueshima(Kindai University), Kinuyo Hatanaka(Union Hospital), Young So, Takashi Matsunaga(Shiga University of Medical Science), Michiie Sakamoto(Keio University), Yasutsugu Takada(Kyoto University), Se Hyung Kim, Jae Young Lee(Chungnam National University), Soo Jin Kim, Jeong Min Lee(Seoul National University), Tatsuo Inoue, Wenlin Du, Hiroyoshi Isoda, Mikiko Ueda, Byung Ihn Choi(Chung-Ang University Hospital), Yuusuke Hirokawa, Seiji Haji(Kindai University), Hiroshi Kasugai(Osaka International Cancer Institute), Taisuke Mori(National Cancer Centre Japan), Toshiya Shibata
Cited by 1
Related Papers
Pembrolizumab in patients with advanced hepatocellular carcinoma previously treated with sorafenib (KEYNOTE-224): a non-randomised, open-label phase 2 trial
|The Lancet Oncology|2018|2.5k
Pembrolizumab As Second-Line Therapy in Patients With Advanced Hepatocellular Carcinoma in KEYNOTE-240: A Randomized, Double-Blind, Phase III Trial
|Journal of Clinical Oncology|2019|1.8k
Development of a Prokaryotic Universal Primer for Simultaneous Analysis of Bacteria and Archaea Using Next-Generation Sequencing
|PLoS ONE|2014|1.5k
Tremelimumab plus Durvalumab in Unresectable Hepatocellular Carcinoma
|NEJM Evidence|2022|1.4k
Global patterns of hepatocellular carcinoma management from diagnosis to death: the <scp>BRIDGE</scp> Study
|Liver International|2015|1.3k